FRANKLIN, Tenn. - Clover Health Investments, Corp. (NASDAQ:CLOV), a healthcare technology company, announced today that its Medicare Advantage (MA) plans have received upgraded Star ratings from the Centers for Medicare and Medicaid Services (CMS) for 2025. The company's Preferred Provider Organization (PPO) plans have been elevated to a 4-Star rating, while its Health Maintenance Organization (HMO) plan has achieved a 3.5-Star rating.
These ratings are critical as they influence the payments plans receive from CMS for the following year, in this case, 2026. The Star rating system, which ranges from 1 to 5 Stars, assesses plan performance across various measures, including healthcare quality and drug plan services.
Clover Health's improved ratings reflect its strong performance in several key areas. Notably, the company received a near-perfect score of 4.94 out of 5 Stars on the Healthcare Effectiveness Data and Information Set (HEDIS), which evaluates a plan's effectiveness in managing and providing preventive services for health conditions like diabetes, cancer, and heart disease.
Andrew Toy, CEO of Clover Health, attributes the high ratings to the company's focus on improving healthcare outcomes and its investment in quality care. The company's technology, Clover Assistant, provides physicians with real-time insights to enhance care quality through better preventive services and care coordination.
Jamie Reynoso, CEO of Medicare Advantage at Clover Health, sees the higher Star ratings as an opportunity to reinvest in competitive benefits, potentially increasing value for members and supporting membership growth. The ratings are seen as a result of foundational improvements made over the past years by the company.
Clover Health, which operates PPO and HMO Medicare Advantage plans, emphasizes its commitment to providing access to high-quality healthcare, especially for seniors who have historically lacked affordable options. The company's subsidiary, Counterpart Health, aims to extend the benefits of Clover's data-driven technology platform to a broader audience, enhancing patient outcomes and reducing healthcare costs nationwide.
The information provided is based on a press release statement by Clover Health, which is a PPO and HMO with a Medicare contract, subject to annual renewal. The company's statements have not been endorsed by CMS and reflect the views of the company's authors. Clover Health has reported on the impact of its technology on medication adherence and the management of chronic conditions such as diabetes and chronic kidney disease.
In other recent news, Clover Health Investments, Corp. reported a GAAP net income of $7.4 million, a significant turnaround due to a strong second-quarter revenue performance and an improved medical cost ratio (MCR). The company also announced a multi-year agreement with The Iowa Clinic, P.C., marking a significant expansion for its subsidiary, Counterpart Health, in the Midwest. Following these developments, Canaccord Genuity adjusted its outlook on Clover Health, raising the price target while maintaining a Buy rating.
The Securities and Exchange Commission (SEC) has concluded its investigation into Clover Health and does not intend to recommend enforcement action. In leadership changes, Joseph Brand was appointed as the new Chief Operating Officer, and Thomas L. Tran was added to the Board of Directors.
UBS initiated coverage on Clover Health stock, assigning a Neutral rating and setting a price target of $4.00. The firm's projections for Clover Health's future indicate revenue of $1.6 billion in 2025 and $1.8 billion in 2026, which surpasses the consensus estimates. These are some of the recent developments at Clover Health.
InvestingPro Insights
Clover Health's recent Star rating upgrades align with some positive financial indicators revealed by InvestingPro data. The company's revenue for the last twelve months as of Q2 2023 stood at $2.09 billion, reflecting its significant market presence in the Medicare Advantage space. This financial performance is particularly noteworthy given the company's focus on improving healthcare outcomes and investing in quality care, as mentioned in the article.
An InvestingPro Tip highlights that Clover Health holds more cash than debt on its balance sheet, which could provide the company with financial flexibility to further invest in its technology and care quality initiatives. This strong financial position may support the company's ability to reinvest in competitive benefits, as suggested by Jamie Reynoso in the article.
Another relevant InvestingPro Tip indicates that the stock has shown a strong return over the last three months, with a remarkable 191.79% price total return. This positive market sentiment could be partly attributed to the company's improving operational performance, as evidenced by the upgraded Star ratings.
It's worth noting that InvestingPro offers 11 additional tips for Clover Health, providing investors with a more comprehensive analysis of the company's financial health and market position. These insights can be particularly valuable for those looking to understand the full impact of Clover Health's operational improvements on its financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.